Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.
Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Ascelia Pharma is expected to release its Q3 2026 interim report on 5 November 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company’s latest developments in a live online event.
Ascelia Pharma yesterday disclosed the findings from its 9 September Type A meeting with the FDA and discussed them at an investor call. The headline is that the FDA maintains its position that additional clinical evidence is required, but no longer presents a new clinical study with new patients as the only way to generate it.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Ascelia Pharma offentliggjorde søndag, at selskabet har modtaget det officielle mødereferat fra Type A-mødet med FDA den 9. september. Copenhagen Capital meldte fredag ud, at bestyrelsen iværksætter et tilbagekøb af egne aktier for op til kr. 10,0 mio., fordelt med kr. 5,0 mio. på hver af de to aktieklasser. Efter NORDENs fjerde opjustering af forventningerne til 2026, som kom 6. oktober forud for Q3-regnskabet, har vi opdateret vores investeringscase.
Today, Ascelia Pharma CEO Magnus Corfitzen presented the company’s Q2 2026 results and answered questions from the audience during a live online event.
Ascelia Pharma is expected to release its Q2 2026 results on 20 August 2026. The following day at 10:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event.
I dag afholder vi fem online investorevents. Kl. 10:00 præsenterer Ascelia Pharma CEO Magnus Corfitzen resultaterne for Q2 2026. Kl. 11:00 præsenterer Lundbeck Jens Høyer, Vice President & Head of Investor Relations, halvårsrapporten for H1 2026. Kl. 12:00 præsenterer SP Group CEO Lars Bering og CFO Allan Jeppesen regnskabet for 2. kvartal 2026. Kl. 13:00 præsenterer WindowMaster CEO Erik Boyter og CFO Steen Overgaard Sørensen halvårsrapporten for H1 2026. Kl. 14:00 gennemgår North Medias ledelse regnskabet for 2. kvartal 2026. Tilmeld dig og stil dine spørgsmål allerede nu.
Udsigt til flad åbning i Europa, hvor regnskaber kan sætte retningen. Fokus på regnskabsaktuelle ALK, Ascelia Pharma, Gubra, BioPorto og ExprS2ion. Gæst i studiet her til morgen er Copenhagen Capitals direktør, Rasmus Greis.
* Type A meeting with the FDA scheduled for September 9 * Implementing cost-saving measures * Conf call at 10am CET Recent and upcoming relevant events Following the July 2, 2026 Complete Response Letter for Orviglance, which cited concerns over the ...
